Publication Name	World Journal of Clinical Cases
Manuscript ID	59400
Country	Japan

Received	2020-09-10 01:19
Peer-Review Started	2020-09-10 01:19
First Decision by Editorial Office Director	2020-09-23 05:23
Return for Revision	2020-09-23 05:23
Revised	2020-10-01 07:20
Publication Fee Transferred
Second Decision by Editor	2020-10-19 06:43
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2020-10-20 02:58
Articles in Press	2020-10-20 02:58
Edit the Manuscript by Language Editor
Typeset the Manuscript	2020-11-02 16:35
Publish the Manuscript Online	2020-11-06 09:07

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Infectious Diseases
Manuscript Type	Case Report
Article Title	Nafamostat mesylate-induced hyperkalemia in critically ill patients with COVID-19: Four case reports
Manuscript Source	Unsolicited Manuscript
All Author List	Masaki Okajima, Yoshinori Takahashi, Takaaki Kaji, Naohiko Ogawa and Hideyuki Mouri
ORCID	Author(s) ORCID Number Masaki Okajima http://orcid.org/0000-0003-0184-3483 Yoshinori Takahashi http://orcid.org/0000-0001-8976-9614 Takaaki Kaji http://orcid.org/0000-0003-4932-0227 Naohiko Ogawa http://orcid.org/0000-0001-9495-7951 Hideyuki Mouri http://orcid.org/0000-0003-2478-0016
Funding Agency and Grant Number
Corresponding Author	Masaki Okajima, MD, PhD, Assistant Professor, Intensive Care Unit, Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa 920-8641, Ishikawa, Japan. mmokaji@gmail.com
Key Words	COVID-19; Nafamostat; Hyperkalemia; Disseminated intravascular coagulation; Respiratory insufficiency; Case report
Core Tip	The coronavirus disease 2019 (COVID-19) pandemic is a rapidly evolving situation. Nafamostat mesylate (NM) may prove to effective against COVID-19. However, our case series shows NM-induced hyperkalemia in 4 patients with COVID-19. Monitoring serum potassium levels after NM-initiation is imperative.
Publish Date	2020-11-06 09:07
Citation	Okajima M, Takahashi Y, Kaji T, Ogawa N, Mouri H. Nafamostat mesylate-induced hyperkalemia in critically ill patients with COVID-19: Four case reports. World J Clin Cases 2020; 8(21): 5320-5325
URL	https://www.wjgnet.com/2307-8960/full/v8/i21/5320.htm
DOI	https://dx.doi.org/10.12998/wjcc.v8.i21.5320

Full Article (PDF)	WJCC-8-5320.pdf
Full Article (Word)	WJCC-8-5320.docx
CARE Checklist–2016	59400-CARE-Checklist–2016-revision.pdf
Manuscript File	59400_Auto_Edited.docx
Answering Reviewers	59400-Answering reviewers.pdf
Audio Core Tip	59400-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	59400-Conflict-of-interest statement.pdf
Copyright License Agreement	59400-Copyright license agreement.pdf
Signed Informed Consent Form(s) or Document(s)	59400-Informed consent statement.pdf
Non-Native Speakers of English Editing Certificate	59400-Language certificate.pdf
Peer-review Report	59400-Peer-review(s).pdf
Scientific Misconduct Check	59400-Scientific misconduct check.pdf
Scientific Editor Work List	59400-Scientific editor work list.pdf
CrossCheck Report	59400-CrossCheck report.pdf